Skip to content Skip to footer
Subscribe Now
NEWS

Halozyme Therapeutics to Acquire Elektrofi for ~$900M, Expanding its Drug Delivery Offerings

Shots:Halozyme Therapeutics has entered into a definitive agreement to acquire Elektrofi, incl. its Hypercon technology, which enables biologic formulations at concentrations of 400-500mg/mlAs per the deal, Elektrofi will receive $750M upfront, with up to three $50M milestone payments contingent on regulatory approvals of three separate Hypercon products; closing expected in Q4’25As a result…
October 3, 2025

Read more

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots
VIEWPOINTS

Roadblocks to Specialty Medicines Access: Colin Banas from DrFirst in Conversation with PharmaShots 

Shots: Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
August 20, 2025

Read more

VIEWPOINTS

Healthcare Marketing: Tom Donnelly from Supreme Group in a Stimulating Dialogue Exchange with PharmaShots 

Shots: Supreme Group recently announced its 8th acquisition, adding Nimble Works and Vital Works to its portfolio, strengthening its presence in healthcare marketing and communications The acquisition brings together Nimble Works’ insight-driven creative strengths and Vital Works’ performance-focused digital expertise to navigate complex healthcare domains and accelerate data-driven growth marketing Tom Donnelly, CEO of Supreme…
August 6, 2025

Read more

Intas & Coherus
NEWS

Intas Pharmaceuticals Completes the Acquisition of Coherus BioSciences’ Udenyca (Biosimilar, Neulasta) 

Shots: Intas Pharmaceuticals, through its Accord subsidiaries, has completed the acquisition of Coherus BioSciences’ Udenyca (pegfilgrastim-cbqv), a biosimilar of Neulasta  With the acquisition, Accord BioPharma, Intas’ U.S. specialty arm, continues Udenyca commercialization, offering patient-friendly administration options autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS) Udenyca is a leukocyte growth factor used to reduce infection risk in…
August 6, 2025

Read more

Viewpoints_Tahi Ahmadi
VIEWPOINTS

Enhancing Capabilities: Tahi Ahmadi from Genmab in a Riveting Dialogue Exchange with PharmaShots

Shots: Recently, Genmab acquired ProfoundBio in a strategic move to strengthen its position in the ADC space. With this acquisition, Genmab gets ProfoundBio’s novel ADC technology platforms Today, at PharmaShots, we have Tahi Ahmadi, EVP and Chief Medical Officer at Genmab, sharing insights from the recent acquisition of ProfoundBio by Genmab With this acquisition, Genmab…
July 29, 2024

Read more

VIEWPOINTS_Nathan McCutcheon_2023
VIEWPOINTS

Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi

Shots: Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi  Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline  The acquisition provides Shionogi exclusive development, manufacturing,…
October 16, 2023

Read more

VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023
VIEWPOINTS

Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition

Shots:Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platformMark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
May 4, 2023

Read more

Load more